GVR Report cover Animal Vaccines Market Size, Share & Trends Report

Animal Vaccines Market Size, Share & Trends Analysis Report By Product, By Animal Type (Poultry, Aqua, Ruminants, Companion), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2021 - 2028

  • Published Date: May, 2021
  • Base Year for Estimate: 2020
  • Report ID: GVR-2-68038-053-8
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2019
  • Number of Pages: 150

Report Overview

The global animal vaccines market size was valued at USD 9.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.4% from 2021 to 2028. The perpetual introduction of technologically advanced vaccines and the outbreak of livestock diseases have contributed to the changing market dynamics. The market has experienced a shift of trend from live attenuated vaccines to DNA vaccines and is swiftly adopting recombinant vaccine solutions.

U.S. animal vaccines market size, by product, 2016 - 2028 (USD Million)

The market for animal vaccines is expected to remain innovation-led, with frequent acquisitions and strategic alliances. Product development along with competent distribution channels will be key for competitive advantage. Increasing demand for animal-derived food products and regulatory mandates, along with the growing livestock population is also expected to fuel the market growth.

The COVID-19 pandemic has impacted all industries, including animal vaccines. Currently, OIE has confirmed that no animals can spread this virus. However, human-to-animal transmission has been reported in a few countries. IDEXX Laboratories and other companies have tested a large number of dogs & cats for the virus, with test results being negative. In the initial months of the pandemic, there was speculation that it may spread through birds, which negatively impacted the livestock industry. In the U.S., several pig and poultry processing plants shut down after the major outbreak. The poultry sector of India has already lost around USD 1 billion due to fears and concerns about the novel coronavirus.

In December 2020, a bird flu outbreak was reported in 9 Indian states. Due to this, the price of poultry products has gone down, severely affecting the overall livestock industry. According to the Poultry Federation of India, chicken consumption has reduced to 50%, with a drop of 30% the prices, as of December 2020. While most of the Asian countries have adopted vaccination policies, India has primarily resorted to the culling of birds. Punjab and Haryana state governments are close to legalizing vaccinations, which can positively impact the market.

The increasing prevalence of zoonotic diseases can negatively impact human lives, which is likely to boost the demand for animal vaccines. In May 2019, the CDC, in collaboration with USDA and the U.S. Department of the Interior, released a list of top 8 infectious diseases that can easily spread from animals to humans. These include salmonellosis, zoonotic influenza, West Nile virus, coronavirus, plague, rabies, Lyme disease, and brucellosis. Therefore, the CDC is undertaking initiatives to protect people from zoonotic diseases.

Product Insights

The attenuated live vaccines segment dominated the market for animal vaccines and accounted for the largest revenue share of over 36.0% in 2020. Live attenuation is the oldest vaccination method used in the veterinary field. This method is also under trial for the development of additional applications. Some of these alternatives include the development of protein subunit vaccines for swine, which are given intramuscularly. These products aid in reducing the mortality rate and improve the life span of disease-affected swine.

The recombinant vaccine segment is expected to exhibit lucrative growth over the forecast period. These vaccines help reduce the risk of pathogenicity in animals after vaccination. Recombinant vaccines are also expected to help achieve vaccination against multiple virus strains, as recombinants can carry multiple gene inserts. These vaccine formulations are able to avoid the need for adjuvants, increase the viability of the vaccine, and improve stability. Some of the recombinant vaccines available for veterinary medicine are vaccines against canine distemper, pseudorabies, Newcastle disease, Lyme disease, and avian influenza.

Animal Type Insights

The ruminants segment dominated the animal vaccines market and accounted for the largest revenue share of over 25.0% in 2020. The dominance is attributed to the factors such as rising livestock population, supportive government initiatives coupled with the outbreak of diseases among cattle, sheep. In 2019, around 1,200 PPR outbreaks were recorded at a global level as compared to 3,500 in 2015. This decline was the result of a vaccination campaign conducted by FAO & partners in more than 50 countries which are further propelling the market.

Global animal vaccines market share, by animal type, 2020 (%)

On the other hand, the poultry segment is expected to exhibit the fastest growth during the forecast period. High consumption of poultry products on a daily basis is a major factor contributing to the growth of this segment. It is estimated that there will be an approximately 20% increase in the demand for poultry products by 2028. A wide range of vaccines, feed, and pharmaceuticals are used to yield high-quality poultry products, which broadens the scope for growth of this segment. In addition, the poultry segment is identified as the top investment area by animal vaccine market players owing to the high demand for poultry products and growing consumer awareness.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 26.6% in 2020. The region is expected to remain dominant throughout the forecast period. This large share can be attributed to the high prevalence of livestock and zoonotic diseases leading to large-scale animal deaths. In addition, the large presence of well-established pharmaceutical firms that are consistently striving for wide commercialization of their vaccines and augmenting their geographical reach is expected to boost the market growth. In addition, rising incidence of canine disorders, in turn, adoption of vaccination for the same coupled with the rising pet population in the U.S. are some of the key factors contributing to the expansion of the market share of the region.

In Asia Pacific, the market is expected to show the fastest growth rate during the forecast period. The anticipated rise in the livestock population and government initiatives especially in developing economies are some of the prime factors expected to boost the market growth in the region. According to the National Dairy Development Board 2019, India has a cattle population of 192.5 million. Hence such a huge cattle population in the country calls for vaccine demand. The market is driven by high R&D expenditure by many major players combined with rising attempts for commercialization of veterinary vaccines and inoculations at tolerably low prices.

Key Companies & Market Share Insights

The market is highly competitive and marked by the presence of various small and large animal vaccine manufacturers. The key parameters affecting competition include rapid adoption of veterinary preventive injections coupled with government-aided bulk purchase of veterinary vaccines.

In addition, in an attempt to retain share and diversify the product portfolio, major players are frequently opting for various strategies such as mergers and acquisitions strategies, partnerships, and new product launches. For instance, in February 2021, Ceva partnered with the French National Research Institute for Agriculture, Food, and Environment (INRAE), for R&D in the prevention of infectious diseases from animal origin and improvement of animal health. In January 2021, Zoetis launched the Poulvac Procerta HVT-IBD vaccine for the protection of poultry against Infectious Bursal Disease (IBD). This added to the company’s line of recombinant vector vaccines. Some of the prominent players in the animal vaccines market include:

  • Merck & Co., Inc.

  • Zoetis

  • Boehringer Ingelheim International GmbH

  • Virbac,

  • Biogénesis Bagó,

  • Indian Immunologicals Ltd.

  • Elanco

  • Ceva

  • Phibro Animal Health Corporation

  • Neogen Corporation

  • Intas Pharmaceuticals Ltd

  • Ourofino Saúde Animal

Animal Vaccines Market Report Scope

Report Attribute


Market size value in 2021

USD 9.8 billion

Revenue forecast in 2028

USD 16.1 billion

Growth Rate

CAGR of 7.4% from 2021 to 2028

Base year for estimation


Historical data

2016 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, animal type, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; Japan; India; Australia, Brazil; Mexico; Argentina, South Africa; Saudi Arabia

Key companies profiled

Merck & Co., Inc.; Zoetis; Boehringer Ingelheim International GmbH; Virbac; Biogénesis Bagó; Indian Immunologicals Ltd.; Elanco; Ceva; Phibro Animal Health Corporation; Neogen Corporation; Intas Pharmaceuticals Ltd.; Ourofino Saúde Animal

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global animal vaccines market report on the basis of product, animal type, and region:

  • Product Outlook (Revenue, USD Million, 2016 - 2028)

    • Attenuated Live Vaccines

    • Inactivated Vaccines

    • Subunit Vaccines

    • DNA Vaccines

    • Recombinant Vaccines

  • Animal Type Outlook (Revenue, USD Million, 2016 - 2028)

    • Poultry

      • Infectious Bronchitis

      • Avian Influenza

      • Marek's Disease

      • Newcastle Disease

      • Salmonella

      • Others

    • Aqua

      • Bacterial

      • Viral

      • Others

    • Ruminants

      • Foot & mouth disease (FMD)

      • Lumpy skin

      • Rotavirus

      • Coronavirus

      • E. Coli

      • Others

    • Companion

      • Canine

        • Distemper

        • Kennel cough (Parainfluenza)

        • Parvovirus

        • Canine herpes

        • Lyme Disease

        • Rabies

      • Feline

        • Rhinotracheitis

        • Calicivirus

        • Coronavirus

        • Panleukopenia

        • Rabies

    • Swine

      • Swine Influenza

      • Classical Swine Fever (CSF)

      • Porcine Parvovirus (PPV)

      • Porcine Circovirus type 2 (PCV2)

      • M.Hyo

      • Actinobacillus Pleuropneumoniae

      • PRRS

      • Foot & Mouth Disease

      • Pseudorabies

      • PEDV (coronavirus)

      • Others

  • Regional Outlook (Revenue, USD Million, 2016 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • India

      • China

      • Japan

      • Australia

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.